Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS polymerization, thereby reducing sickling and hemolysis, and increasing the half-life of red blood cells. This is believed…
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Oxbryta (Voxelotor) for Sickle Cell Disease
Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS polymerization, thereby reducing sickling and hemolysis, and increasing the half-life of red blood cells. This is believed…
Colon Capsule Endoscopy for Colorectal Cancer Screening, Diagnosis, and Surveillance
Health Problem: Colorectal cancer (CRC) is the second leading cause of cancer death in men and the third in women. Although screening for CRC has been found to reduce CRC mortality, many patients do not undergo the recommended screening.
Technology Description: Colon capsule endoscopy…
Cablivi (Caplacizumab-yhdp)
Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to platelets to prevent the early stages of blood clot formation. Nanobodies are much smaller than conventional monoc…
Cablivi (Caplacizumab-yhdp)
Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to platelets to prevent the early stages of blood clot formation. Nanobodies are much smaller than conventional monoc…
Cold Compression Therapy for Patients Undergoing Orthopedic Procedures to Major Joints (Other than Knee)
Health Problem: Acute postoperative pain and swelling is common following orthopedic procedures. Inadequately controlled pain negatively affects quality of life and recovery of function and may result in an increase in morbidity, recovery time, opioid use, and risk of complications or persistent postsurgical pain.
Genetic Screening of Newborns for Risk of Hearing Loss
This report evaluates the clinical utility of genetic screening of newborns for risk of hearing loss.
Genetic Screening of Newborns for Risk of Hearing Loss
This report evaluates the clinical utility of genetic screening of newborns for risk of hearing loss.
Human Amniotic Membrane Injections for Treatment of Chronic Plantar Fasciitis
Health Problem: Plantar fasciitis (PF) is a progressive degenerative disorder of the plantar fascia, a fibrous band of tissue that runs along the bottom of the foot that connects the heel bone to each of the toes.
Technology Description: Developments in how amniotic tissue is prepared …
Givlaari (Givosiran) for Acute Hepatic Porphyria
Givlaari is a subcutaneously administered ribonucleic acid interference (RNAi) agent that inhibits delta-aminolevulinate synthase 1 (ALAS1) synthesis, a key regulator of the heme biosynthetic pathway in the liver. Givlaari is believed to reduce ALAS1 levels, thereby decreasing delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Decreasing ALA and PBG levels to n…